IDH mutations have been targeted by small molecule inhibitors, which are designed to inhibit the 2-HG production and currently are tested in patients with IDH-mutated glioma in four clinical trials (NCT03343197, NCT04056910, NCT02073994, NCT04195555). Here, IDH2 is linked to central nervous system cancer.